Headaches are a common symptom of a stressful lifestyle, your body not feeling well and other issues. While headaches can be dealt with easily, migraines are not so easy to handle. Migraines are a type of headache that feels like severe throbbing and pulsing sensation, almost like you are hearing your own heartbeat in your brain, usually on one side of the brain. Many people believe that migraines are not that big of a deal because you just have to deal with the pain, but that is not all migraine is, some people find it very difficult to do their daily tasks as they experience dizzying spells, nausea and extreme sensitivity to light and sound! These attacks can last hours and make it difficult for people to go about their daily lives as well. While there are medications available for migraine patients, these medications need time to take effect, so you may be in a lot of pain, but there are not many quick reliefs you can have in place other than learning the symptoms of a migraine attack and taking medication before it happens. But a new approval by the FDA may change this!

The U.S. Food and Drug Administration (FDA) has approved Symbravo, a new medicine to treat acute migraine attacks in adults. This means adults can now use Symbravo to get relief from their migraine symptoms. The FDA's decision was based on the results of three big studies, called Phase 3 trials. These trials involved over 21,000 migraine attacks, so the FDA has a lot of information about how well Symbravo works and how safe it is. The FDA only approves medicines that have been shown to be both safe and effective through a thorough testing process.

Importance of New Treatment Option

"Migraine attacks can happen suddenly and really mess up people's lives. It's estimated that over 39 million people in the U.S. alone get migraines," said Herriot Tabuteau, M.D., CEO of Axsome Therapeutics told US News. This shows how common migraines are and how important it is to have good treatments. "Symbravo gives patients and doctors a new option that can quickly stop a migraine attack, keep it away, and let people get back to their normal activities, all with just one dose." Having a medicine that can give fast and long-lasting relief from migraine pain is a big deal for millions of people. This new treatment is a real step forward in how we treat migraines.

Symbravo Trial Results, How Was It Approved

The trials took place in 3 steps, the Momentum trial study focused on people whose migraines had moderate to severe pain. The results showed that a lot more people taking Symbravo felt pain-free two hours after taking the medicine compared to those who took a placebo which is a dummy pill. Even better, many people felt relief for up to 24 and even 48 hours after just one dose. This long-lasting relief is really important for people with migraines because it means they can get back to their normal lives without worrying about the pain coming back. The study also looked at how many people were free from their worst symptom, like sensitivity to light or sound, or nausea. Symbravo worked better than the placebo in this area too.

While the intercept trial looked at people who took Symbravo when their migraine pain was still mild. Even when the pain was just starting, Symbravo was effective. The results were similar to the MOMENTUM trial, with many people getting pain relief and relief from their worst symptoms. Treating migraines early is often better because it can stop the pain from getting really bad.

And lastly the Movement trial which was to see how safe the medication is when people take it regularly. This study followed 706 people who had at least two migraines a month. The most common side effects people experienced were sleepiness and dizziness. While these side effects are important to know about, the study showed that Symbravo is generally safe for people to use on a regular basis.

South Africa's National Department of Health has announced that it has received a first consignment of 37,920 doses of the groundbreaking, six-monthly HIV prevention injection, Lenacapavir.

Lenacapavir is the first twice-yearly injectable pre-exposure prophylaxis (PrEP) product that can help tackle the burden of HIV worldwide.

South Africa has the world's largest HIV-positive population of approximately 8 million people, with over 6 million currently on antiretroviral treatment.

“The department will, in the next few weeks, announce the official launch of this game changer where the phased implementation plan will be outlined,” said department spokesperson Foster Mohale, in a statement.

"Lenacapavir is preventive medicine, not a vaccine, considered one of the most exciting HIV prevention advances in years," Mohale said.

The Department noted that the medicine is expected to be sustain nearly half a million people in South Africa over the next two years, the statement said, adding that is will be officially rolled out in May.

Notably, the initial phase will target high-incidence districts and vulnerable groups.

What Is Lenacapavir?

Lenacapavir is a critical tool for reaching the Global AIDS Strategy goal of ending AIDS as a public health threat by 2030.

Lenacapavir injection as an additional PrEP option offers a highly effective, long-acting alternative to daily oral pills and other shorter-acting options.

With just two doses per year, lenacapavir is a transformative step forward in protecting people at risk of HIV -- particularly those who face challenges with daily adherence, stigma, or access to health care.

Marketed under the brand name Yeztugo, lenacapavir, developed by global pharma major Gilead Sciences, costs $28,218 per person per year.

However, it is being provided to South Africa through a $29-million USD grant from the Global Fund.

The shot was tested in two major studies involving high-risk groups: one with young women and teenage girls in South Africa and Uganda, and another with gay men and gender-diverse individuals in several countries. In both cases, the results were striking.

The women who received the shot had zero new HIV infections, compared to around 2% in those on daily pills. In the second study, the twice-yearly shot proved just as effective for men and gender non-conforming individuals.

“This really has the possibility of ending HIV transmission,” said Greg Millett of amfAR, The Foundation for AIDS Research.

Lenacapavir: How Does It Work?

Yeztugo is administered as two small injections in the abdomen, forming a medication "depot" that slowly releases the drug into the body over six months.

However, people must test negative for HIV before receiving it, as it doesn’t treat existing infections or prevent other sexually transmitted diseases.

Lenacapavir: Why Access Is A Challenge?

Despite its potential, concerns remain over who will actually benefit from lenacapavir.

In the US, only about 400,000 people currently use any form of PrEP — a small fraction of those who could benefit. And structural issues like cuts to public health funding, limited insurance access, and stigma pose significant barriers.

Globally, the challenge is even greater. While Gilead has struck deals with six generic drug makers, including four Indian, to provide low-cost versions of the shot for 120 low-income countries, critics argue that middle-income nations have been left out.

UNAIDS Executive Director Winnie Byanyima noted that at current prices, the shot “will change nothing” for many who need it.

Rotavirus has been increasingly detected in wastewater in several California cities, sparking concerns about the risk of the deadly and highly contagious virus in young children.

The virus is highly contagious and known for causing fever, vomiting, and severe watery diarrhea among small children. Older children and adults with weakened immune systems also are vulnerable, according to the US Centers for Disease Control and Prevention (CDC).

As per data from WastewaterSCAN, “high concentrations” of rotavirus have been found in Marin, Redwood City, San Jose, and Santa Cruz, while moderate concentrations have been found in Sacramento, Davis, San Francisco, Sunnyvale, Fremont, Vallejo, and Novato, The Sacramento Bee reported.

"It's extremely contagious," Dr. Monica Gandhi, an infectious disease specialist at UC San Francisco, told SFGATE Thursday, explaining that rotavirus is one of the lesser-known gastrointestinal illnesses.

According to UCSF, approximately 50,000 children in the US are hospitalized with it each year.

What Is Rotavirus?

Rotaviruses are the most common cause of severe diarrheal disease in infants and young children worldwide.

The virus, a member of the reovirus family, affects the vast majority of children worldwide before the age of 3 years, and in most developing countries before the first birthday.

The virus causing the infection was discovered in 1973, according to the National Institutes of Health. It causes severe diarrhea, often leading to dehydration, which can be severe, requiring hospitalization.

It is transmitted by

• the fecal-oral route
• directly from person to person,
• indirectly through contaminated objects.

• transient loose stools
• severe diarrhea
• vomiting,
• dehydration,
• electrolyte disturbances,
• shock,
• death if rehydration is not provided.

Is Rotavirus Preventable By Vaccine?

WHO-prequalified rotavirus vaccines have been available since 2008, and there are currently four vaccines available. They are all live, oral vaccines.

RotaTeq, Rotavac, and ROTASIIL should be administered in a 3-dose schedule, while a 2-dose schedule should be used for Rotarix. A minimum interval of 4 weeks should be maintained between doses, the WHO said.

In addition, key measures to prevent diarrhea include the following:

• access to safe drinking water
• use of improved sanitation
• hand washing with soap
• exclusive breastfeeding for the first six months of life
• good personal and food hygiene
• health education about how infections spread.

Resident doctors in the UK have launched a six-day strike in a dispute with the government over pay.

Tens of thousands of medics have walked out of the National Health Service (NHS) in England on Tuesday, in the 15th strike since March 2023. Their demand: “full pay restoration”.

The six-day walkout comes as the doctors’ group rejected an offer made by the government in March.

According to the British Medical Association (BMA), the government’s proposal failed to reverse years of pay erosion and staffing pressures.

The BMA represents about 55,000 of the resident doctors - formerly known as ‌junior doctors - ⁠who make up nearly half of the medical workforce.

The strike is due to run until the morning of April 13, after a 48-hour ultimatum from Prime Minister Keir Starmer passed without agreement.

Doctors Strike: What Is The Reason?

The BMA argues that doctors are still being paid a fifth less than they were in 2008, once inflation is taken into account. This is despite receiving pay rises worth 33 percent over the past four years.

Dr Jack Fletcher, chair of the BMA's resident doctor committee, told BBC Radio 4's Today program he was "genuinely very sorry" to patients who had care postponed due to the strike, but noted that such delays also occurred "without strike action" because of a lack of specialists and GPs.

"The way out of this is to get around the negotiating table, as we were for eight or so weeks, talk constructively to get a deal, to get us out of this.

Dr Emma Runswick, deputy chair of the BMA Council, told BBC Breakfast they had been close to reaching a deal but "the government decided to move the goalposts quite last minute to reduce the level of investment they were prepared to make".

The 15th NHS Doctors' Strike: How Patients Will Be Affected

The strike began at 07:00 BST on Tuesday and promises to cause significant disruption to services.

Dr Melissa Ryan, 45, a pediatric registrar, said she was frustrated that the government was cutting training places and some children were waiting years for assessments, the BBC reported.

The pediatrician who joined dozens of resident doctors in the six-day strike over jobs and pay has said the NHS may "end up without doctors" if the long-running dispute continues.

However, senior medics have being called in to provide cover in emergency settings, still some pre-planned treatments and appointments may get cancelled.

Meanwhile, the NHS has urged patients not to put off seeking help if needed, saying those with emergency and urgent needs should use 999 and 111 as normal, the BBC reported.

While GP services are largely unaffected, the NHS advised patients with prior appointments and treatments scheduled to attend unless told otherwise.

Strikes Costing The NHS £50 Million Daily

Health Secretary Wes Streeting told BBC Breakfast that 95 percent of appointments were still in place. He also apologized to people affected by cancellations, saying they "deserve better".

He criticized the BMA for not accepting the government’s latest offer and said the government had negotiated with the BMA "in good faith".

According to the British government, the strikes were costing the NHS £50m a day, meaning the health service had lost around £3bn since industrial action started in March 2023. However, a detailed breakdown of costs has not been set out.

Speaking on Times Radio on Tuesday, Streeting said resident doctors had secured the largest pay uplift of any public sector group under the Labour government, but had rejected the offer without putting forward a counter proposal.